![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: EGFLAM |
Gene summary for EGFLAM |
![]() |
Gene information | Species | Human | Gene symbol | EGFLAM | Gene ID | 133584 |
Gene name | EGF like, fibronectin type III and laminin G domains | |
Gene Alias | AGRINL | |
Cytomap | 5p13.2-p13.1 | |
Gene Type | protein-coding | GO ID | GO:0006022 | UniProtAcc | Q63HQ2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
133584 | EGFLAM | LZE8T | Human | Esophagus | ESCC | 2.72e-03 | 1.65e-01 | 0.067 |
133584 | EGFLAM | P2T-E | Human | Esophagus | ESCC | 2.20e-17 | 3.52e-01 | 0.1177 |
133584 | EGFLAM | P15T-E | Human | Esophagus | ESCC | 3.34e-06 | 1.68e-01 | 0.1149 |
133584 | EGFLAM | P16T-E | Human | Esophagus | ESCC | 2.56e-16 | 2.97e-01 | 0.1153 |
133584 | EGFLAM | P20T-E | Human | Esophagus | ESCC | 1.51e-02 | 1.06e-01 | 0.1124 |
133584 | EGFLAM | P26T-E | Human | Esophagus | ESCC | 1.78e-03 | 9.27e-02 | 0.1276 |
133584 | EGFLAM | P37T-E | Human | Esophagus | ESCC | 4.28e-02 | 1.06e-01 | 0.1371 |
133584 | EGFLAM | P38T-E | Human | Esophagus | ESCC | 2.66e-02 | 1.59e-01 | 0.127 |
133584 | EGFLAM | P56T-E | Human | Esophagus | ESCC | 1.26e-12 | 1.17e+00 | 0.1613 |
133584 | EGFLAM | P74T-E | Human | Esophagus | ESCC | 5.13e-27 | 7.86e-01 | 0.1479 |
133584 | EGFLAM | P76T-E | Human | Esophagus | ESCC | 5.68e-24 | 5.64e-01 | 0.1207 |
133584 | EGFLAM | P80T-E | Human | Esophagus | ESCC | 1.26e-02 | 1.29e-01 | 0.155 |
133584 | EGFLAM | P107T-E | Human | Esophagus | ESCC | 8.98e-03 | 1.68e-01 | 0.171 |
133584 | EGFLAM | P130T-E | Human | Esophagus | ESCC | 4.31e-06 | 2.25e-01 | 0.1676 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![]() | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias | ||
LGIN: Low-grade intraepithelial neoplasias |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003158919 | Esophagus | ESCC | cell-substrate adhesion | 221/8552 | 363/18723 | 3.06e-09 | 6.62e-08 | 221 |
GO:001081020 | Esophagus | ESCC | regulation of cell-substrate adhesion | 144/8552 | 221/18723 | 3.55e-09 | 7.45e-08 | 144 |
GO:004578527 | Esophagus | ESCC | positive regulation of cell adhesion | 255/8552 | 437/18723 | 5.07e-08 | 9.11e-07 | 255 |
GO:00091002 | Esophagus | ESCC | glycoprotein metabolic process | 226/8552 | 387/18723 | 2.64e-07 | 3.94e-06 | 226 |
GO:00067906 | Esophagus | ESCC | sulfur compound metabolic process | 201/8552 | 339/18723 | 2.64e-07 | 3.94e-06 | 201 |
GO:001081126 | Esophagus | ESCC | positive regulation of cell-substrate adhesion | 84/8552 | 123/18723 | 3.18e-07 | 4.50e-06 | 84 |
GO:00182099 | Esophagus | ESCC | peptidyl-serine modification | 196/8552 | 338/18723 | 3.07e-06 | 3.47e-05 | 196 |
GO:00301984 | Esophagus | ESCC | extracellular matrix organization | 171/8552 | 301/18723 | 6.08e-05 | 4.67e-04 | 171 |
GO:00430624 | Esophagus | ESCC | extracellular structure organization | 171/8552 | 302/18723 | 7.73e-05 | 5.76e-04 | 171 |
GO:00452294 | Esophagus | ESCC | external encapsulating structure organization | 172/8552 | 304/18723 | 7.80e-05 | 5.80e-04 | 172 |
GO:0006029 | Esophagus | ESCC | proteoglycan metabolic process | 48/8552 | 79/18723 | 4.93e-03 | 1.89e-02 | 48 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EGFLAM | SNV | Missense_Mutation | c.1898C>T | p.Ser633Phe | p.S633F | Q63HQ2 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-5L-AAT0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
EGFLAM | SNV | Missense_Mutation | c.796N>A | p.Asp266Asn | p.D266N | Q63HQ2 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.998) | TCGA-A8-A07W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | exemestane | SD | |
EGFLAM | SNV | Missense_Mutation | novel | c.694N>T | p.Asp232Tyr | p.D232Y | Q63HQ2 | protein_coding | tolerated_low_confidence(0.05) | benign(0.106) | TCGA-AC-A2FE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
EGFLAM | SNV | Missense_Mutation | c.2072N>A | p.Thr691Asn | p.T691N | Q63HQ2 | protein_coding | tolerated(0.09) | possibly_damaging(0.521) | TCGA-AN-A0XN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
EGFLAM | SNV | Missense_Mutation | novel | c.2696N>C | p.Gly899Ala | p.G899A | Q63HQ2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AQ-A0Y5-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | SD |
EGFLAM | SNV | Missense_Mutation | rs764887956 | c.931C>G | p.Pro311Ala | p.P311A | Q63HQ2 | protein_coding | tolerated(0.06) | benign(0.034) | TCGA-BH-A0HX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adrimycin | SD |
EGFLAM | SNV | Missense_Mutation | c.1219N>G | p.Gln407Glu | p.Q407E | Q63HQ2 | protein_coding | deleterious(0.01) | possibly_damaging(0.868) | TCGA-C8-A12T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
EGFLAM | SNV | Missense_Mutation | rs749175056 | c.1924C>T | p.Arg642Trp | p.R642W | Q63HQ2 | protein_coding | tolerated(0.09) | probably_damaging(0.992) | TCGA-D8-A1XW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD |
EGFLAM | SNV | Missense_Mutation | rs148322152 | c.2332G>A | p.Gly778Arg | p.G778R | Q63HQ2 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD |
EGFLAM | insertion | Frame_Shift_Ins | novel | c.325_326insTTGAAAGCTGCAGAGAGTCATTAAAGACTGAGATGCACTC | p.Glu109ValfsTer62 | p.E109Vfs*62 | Q63HQ2 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |